Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET
2023年5月17日 - 9:00PM
ビジネスワイヤ(英語)
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("AI") and machine learning (“ML”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that Panna Sharma, CEO and
President, will present at the Lytham Partners Spring 2023 Investor
Conference on Thursday, May 18, 2023. The fireside chat-style
webcast will be available to all registered attendees. Details of
the webcast can be found below:
- Lytham Partners Spring 2023 Investor Conference,
Thursday, May 18th at 9:00 a.m. ET. Presenter: Panna Sharma,
CEO & President. Webcast Link:
https://wsw.com/webcast/lytham8/ltrn/2066400
Lantern management will also be participating in one-on-one
virtual investor meetings throughout the conference. To arrange a
meeting with management, please contact Lytham Partners at
1x1@lythampartners.com or register at
https://www.lythampartners.com/spring2023invreg/.
About Lantern Pharma: Lantern Pharma is an AI company
transforming the cost, pace, and timeline of oncology drug
discovery and development. Our proprietary AI and machine learning
(ML) platform, RADR®, leverages over 25 billion oncology-focused
data points and a library of 200+ advanced ML algorithms to help
solve billion-dollar, real-world problems in oncology drug
development. By harnessing the power of AI and with input from
world-class scientific advisors and collaborators, we have
accelerated the development of our growing pipeline of therapies
including eleven cancer indications and an antibody-drug conjugate
(ADC) program. On average, our newly developed drug programs have
been advanced from initial AI insights to first-in-human clinical
trials in 2-3 years and at approximately $1.0-2.0 million per
program.
Our lead development programs include two Phase 2 clinical
programs and multiple upcoming Phase 1 clinical trials anticipated
for 2023. We have also established a wholly-owned subsidiary,
Starlight Therapeutics Inc., to focus exclusively on the clinical
execution of our promising therapies for CNS and brain cancers,
many of which have no effective treatment options. Our AI-driven
pipeline of innovative product candidates is estimated to have a
combined annual market potential of over $15 billion USD and have
the potential to provide life-changing therapies to hundreds of
thousands of cancer patients across the world.
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma Lantern Pharma Newsletter – The Spark: Sign-up
here
Forward-looking Statements: This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates and antibody drug conjugate (ADC) development program;
estimates regarding the development timing for our drug candidates
and ADC development program; expectations and estimates regarding
clinical trial timing and patient enrollment; our research and
development efforts of our drug discovery and ADC programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug or ADC candidate; estimates regarding patient
populations, potential markets and potential market sizes; sales
estimates for our drug and ADC candidates and our plans to discover
and develop drug and ADC candidates and to maximize their
commercial potential by advancing such candidates ourselves or in
collaboration with others. Any statements that are not statements
of historical fact (including, without limitation, statements that
use words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "model," "objective,"
"aim," "upcoming," "should," "will," "would," or the negative of
these words or other similar expressions) should be considered
forward-looking statements. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as (i) the impact
of the COVID-19 pandemic, (ii) the risk that our research and the
research of our collaborators may not be successful, (iii) the risk
that none of our product candidates has received FDA marketing
approval, and we may not be able to successfully initiate, conduct,
or conclude clinical testing for or obtain marketing approval for
our product candidates, (iv) the risk that no drug product based on
our proprietary RADR® AI platform has received FDA marketing
approval or otherwise been incorporated into a commercial product,
and (v) those other factors set forth in the Risk Factors section
in our Annual Report on Form 10-K for the year ended December 31,
2022, filed with the Securities and Exchange Commission on March
20, 2023. You may access our Annual Report on Form 10-K for the
year ended December 31, 2022 under the investor SEC filings tab of
our website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230517005079/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
過去 株価チャート
から 4 2024 まで 5 2024
Lantern Pharma (NASDAQ:LTRN)
過去 株価チャート
から 5 2023 まで 5 2024